Abstract 1166P
Background
In-transit metastases (ITM) in melanoma represent a clinical entity where tumor lesions are found between the primary tumor and the draining lymph node. ITM is associated with worse prognosis. However, a significant subset of patients have discordance with high burden of locoregional relapses, but durable distant progression free survival. We studied two such patients to profile the dynamics and evolution of longitudinal tumor samples and identify mechanisms underlying these heterogeneous phenotypes.
Methods
We used whole exome sequencing (WES), bulk RNAseq, snRNAseq, and high-plex Cyclic Immunofluorescence (CyCIF) imaging to profile 28 biopsies over 7 years from pt1 (acral lentiginous melanoma, with progressive disease) and 22 biopsies over 11 years from pt2 (cutaneous melanoma, with durable remission).
Results
Pt1 (progressive disease) tumors had low to absent levels of immune infiltrate, low tumor mutational burden (TMB) and 5-hmC loss. Phylogenetic analysis revealed co-evolution of seven genetic lineages with multiple independent resistance-associated alterations; the majority of distant metastases emerged from a single lineage characterized by high aneuploidy and TMB, and a likely pathogenic missense mutation in TET2. The brain metastasis diverging early in molecular evolution but emerging late in disease had the highest TMB and aneuploidy. In another lineage, we identified WNT-beta catenin transcriptional signature contributing to TIL exclusion. In contrast, phylogenetic analysis of pt2 (durable remission) revealed six co-evolved genetic lineages with acquisition of mutational signature 11 and high TMB (53 mut/MB) after dacarbazine chemotherapy. In line with this, several tumor samples contained abundant Ki67+ CD8+ TILs and regression-like stromal changes, reflective of an autonomous effective host-immune response leading to a complete remission independent of any systemic therapy.
Conclusions
This study identifies genomic and phenotypic features linked to aggressive phenotypes and distant metastasis, including high aneuploidy, TET2 mutation, and 5hmC loss. Additional spatial analysis (GeoMx) is currently ongoing.
Clinical trial identification
Editorial acknowledgement
Legal entity responsible for the study
The authors.
Funding
Doris Duke foundation.
Disclosure
All authors have declared no conflicts of interest.
Resources from the same session
1100P - Open-label non-randomized phase IB study to characterize the safety, tolerability and recommended dose of tinostamustin in combination with nivolumab in patients with advanced melanoma (ENIGMA)
Presenter: Markus Joerger
Session: Poster session 13
1101P - The effect of LNS8801 in combination with pembrolizumab in patients with treatment-refractory cutaneous melanoma
Presenter: Jordi Rodon
Session: Poster session 13
1102P - Evaluation of surrogate endpoints for overall survival within the RELATIVITY-047 trial
Presenter: Peter Mohr
Session: Poster session 13
1103P - Nivolumab (NIVO) plus relatlimab (RELA) vs NIVO in previously untreated metastatic or unresectable melanoma: 2-year subgroup analyses from RELATIVITY-047
Presenter: Georgina Long
Session: Poster session 13
1104P - Efficacy of immune checkpoint inhibition in metastatic or non-resectable melanoma after failure of adjuvant anti-PD1 treatment: A EUMelareg real-world evidence study
Presenter: Michael Weichenthal
Session: Poster session 13
1105P - First-line nivolumab plus ipilimumab in advanced melanoma patients previously treated with adjuvant systemic therapy
Presenter: Katarzyna Kozak
Session: Poster session 13
1106P - Anti-PD-1 (PD1) monotherapy or in combination with anti-CTLA-4 for metastatic melanoma (MM) patients (pts) with liver metastases (mets)
Presenter: Ines Pires da Silva
Session: Poster session 13
1107P - BRAF mutation status does not impact outcomes with tebentafusp in advanced cutaneous melanoma
Presenter: Alexander Shoushtari
Session: Poster session 13
1108P - Outcomes of patients with unresectable or metastatic melanoma after cessation of immunotherapy following complete response or toxicities
Presenter: Nur Sakinah Zulkifli
Session: Poster session 13